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ABSTRACT 
Nonvalvular atrial fibrillation patients need long-term oral anticoagulant such 
as warfarin. Warfarin has a narrow therapeutic index, high potential for 
interaction with food and drugs and can cause bleeding. Geriatric patients are at 
risk of bleeding. In this study, the efficacy and safety of warfarin and their 
relationship with other factors have been studied in geriatric of warfarin clinic. 
There were 84 patients met the inclusion criteria. Patient's data were retrieved 
from the hospital medical record, medication therapy adherence clinic form, and 
hospital computerized system named "Sistem Pengurusan Pesakit" Warfarin 
therapy is normally presented with the fluctuation of TTR values. TTR values 
were calculated by Rosendaal and Traditional methods. Data descriptive in this 
study presented with mean, frequency and percentage when appropriate. 
Statistical analysis tests used were chi-square, t-test, ANOVA, correlation and 
regression when appropriate with p-value <0.025 (2 tails) is considered 
significant. Efficacy is defined as good when TTR>65% and the safety 
assessment defined as INR>3 which related risk of bleeding. The result showed, 
in term of efficacy, only 44% achieved TTR >65%.The mean TTR for the one 
year period was 60.1% ±19.6% (Rosendaal method) and 51.9% ±18.6%  
(Traditional method). In term of safety, from 1073 INR readings, INR>3 was 
17.39% of total INR. There were 8 patients admitted due to over warfarinization 
which representing 9.4% of total admissions with mean INR 5.4 ± 1.58 while 
mean weekly dosing was 13.6 mg and mean TTR was 50.6%. There were three 
predictors of efficacy, number of missed dose, number of concurrent medication 
and number of visited warfarin clinic (p-value<0.025). In conclusion, a majority 
of geriatric patients were not achieved efficacy, and a few of them had a risk of 
bleeding. Thus, in order to increase majority of geriatric patients achieved 
efficacy and safety of warfarin therapy, more efforts and appropriate strategies 
are needed. 
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